Lv4
756 积分 2022-11-30 加入
Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers
2天前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
9天前
已完结
Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice
9天前
已完结
Acquired resistance mechanisms to osimertinib: The constant battle
10天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
19天前
已完结
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer
25天前
已完结
Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion
25天前
已完结
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
25天前
已完结
A First-in-Human Phase 1/2 Dose-Escalation Study of MAK683 (EED Inhibitor) in Patients with Advanced MalignanciesRunning head: Phase 1/2 study of MAK683 in advanced malignancies
1个月前
已完结
A First-in-Human Phase 1/2 Dose-Escalation Study of MAK683 (EED Inhibitor) in Patients with Advanced Malignancies
1个月前
已完结
皖公网安备34019202002308
